Meeting
2019 ASCO Annual Meeting
Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.
Authors
Paul B. Koller
The University of Texas MD Anderson Cancer Center, Houston, TX
Paul B. Koller , Hagop M. Kantarjian , Elias Jabbour , Sherry A. Pierce , Kathryn Roberts , Hui Zhang , Wenjian Yang , Charles Grenfell Mullighan , Jun J. Yang , Marina Konopleva , Nitin Jain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7023)
DOI
10.1200/JCO.2019.37.15_suppl.7023
Abstract #
7023
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non–small cell lung cancer (aNSCLC).
First Author: Diego Perez Parente
Poster
2021 ASCO Annual Meeting
Retrospective analysis of a novel molecular genetic risk score, “MRplus”, in BCR-ABL1 negative pediatric B-ALL: A single-center experience.
First Author: Sanjeev Kumar Gupta
Poster
2019 ASCO Annual Meeting
Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression.
First Author: WayAnne Watson
Poster
2018 ASCO Annual Meeting
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
First Author: Elias Jabbour